Christopher Ehrlich

Christopher B. Ehrlich is the founder of Prostate Management Diagnostics Inc., founded in 2012, serving as Director since its founding.
Mr. Ehrlich is also the founder of AlgoRx Pharmaceuticals, Inc...
Current positions include Chief Executive Officer & Director at Launch One Acquisition Corp.
since 2024; Chairman & Chief Executive Officer at CERo Therapeutics Holdings, Inc. since 2024; Chief Executive Officer at CERo Therapeutics, Inc. since 2024; Director at QuatRx Pharmaceuticals Co. since 2004; and Director at Prolynx LLC since 2022.
Former positions include Chief Executive Officer at Locust Walk Acquisition Corp.
from 2021 to 2022; Chief Executive Officer & Director at Phoenix Biotech Acquisition Corp.
from 2021 to 2024; Director-Business Development at Genentech, Inc. in 1997; Director at KAI Pharmaceuticals, Inc.; Director at BioMimetic Therapeutics, Inc. from 2004 to 2013; Director at Satori Pharmaceuticals, Inc.; Director at Carbylan Therapeutics, Inc.; Director at Invuity, Inc.; Director at Solace Pharmaceuticals, Inc.; Independent Director at eFFECTOR Therapeutics, Inc. from 2022 to 2024; Director at Xenon Pharmaceuticals, Inc.; Director-Licensing & Business Development at Purdue Pharma LP from 1998 to 1999; Director-Biotechnology Strategy Development at The Lek from 1992 to 1994; Director at CVRx, Inc.; Director-Venture Capital at The U.S.
Russia Investment Fund LLC from 1994 to 1996; Director at Follica, Inc.; Independent Director at Transcept Pharma, Inc. from 2011 to 2013; Managing Director & General Partner at InterWest Venture Management Co. from 2000 to 2013; Senior MD & Head-Global Biotechnology at Locust Walk Partners LLC from 2013 to 2021.
Education includes an undergraduate degree from Dartmouth College conferred in 1992 and an MBAistration from Kellogg School of Management conferred in 1998.